Table 3.
Internal validity of included studies.
| First author | Year | Inadequate allocation sequence generation? | Inadequate allocation concealment? | Inadequate blinding? | Incomplete outcome data? | Selective outcome reporting? | Risk of other bias? |
|---|---|---|---|---|---|---|---|
| Cao [8] | 2012 | Unclear | Unclear | Unclear | No | Yes (lack of some individual CIN data) | No |
| Han [4] | 2013 | No | No | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| Jo [9] | 2008 | No | No | No | No | Yes (lack of some individual CIN data) | No |
| Jo [10] | 2014 | No | Unclear | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| Kaya [11] | 2013 | Unclear | Unclear | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| Leoncini [12] | 2014 | No | Yes (open-label list) | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| Li [13] | 2012 | No | No | No | No | Yes (lack of some individual CIN data) | No |
| Li [14] | 2014 | Unclear | Unclear | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| zhan [15] | 2010 | Unclear | Unclear | Unclear | No | Yes (lack of some individual CIN data) | No |
| Patti [16] | 2011 | No | No | No | No | Yes (lack of some individual CIN data) | No |
| Quintavalle [17] | 2012 | No | No | No | No | Yes (lack of some individual CIN data) | No |
| Toso [18] | 2010 | No | No | No | No | Yes (lack of some individual CIN data) | No |
| Xinwei [19] | 2009 | No | Yes (open-label study) | Yes (open label) | No | Yes (lack of some individual CIN data) | No |
| Zhou [20] | 2009 | Unclear | Unclear | Unclear | No | Yes (lack of some individual CIN data) | No |
CIN = contrast-induced nephropathy.